Clinical use of cardiovascular risk score
Introduction: The American Heart Association has outlined strategic impact goals designed to improve the cardiovascular health of Americans by 20% by the year 2020 including improvements in lifestyle and behavior.
Hypothesis: We assessed the hypothesis that sharing with patients a 7-protein cardiovascular risk score would motivate them to better adhere to cardiovascular risk reduction measures.
Methods: The 7-protein risk score (SomaScan® CVD Secondary Risk Panel, SomaLogic) provides % risk by year for experiencing a cardiovascular event up to 5 years. Patients with stable coronary heart disease received a baseline lifestyle and behavior survey, chart abstraction, and blood draw for the 7-protein risk score. Results were shared with the patient by their physician. One month after receiving the panel results, patients were surveyed on the overall impact of the panel on health, lifestyle, and medication changes.
Results: Among the 198 enrolled patients, 25% had ≥ 20% predicted risk of a cardiovascular event in 5 years. Of the 131 patients with follow-up survey results to date, higher risk patients reported higher rates of desirable lifestyle changes, including healthier diet (Figure 4). Lower risk patients stated they would maintain their lifestyle to remain healthy.
Conclusions: Patients presented with their personal 7-protein cardiovascular risk score were motivated to improve their lifestyle and adherence to medications. The additional motivation from the test results, if sustained long-term, may translate into improved outcomes in patients with coronary heart disease.
More posters
PosterLatest research shows benefit of non-invasive, high-plex protein profiling for liver disease
Learn about using high-plex, aptamer-based protein profiling for NASH research through these three SomaLogic assets. Watch one webinar and download two posters that each highlight NASH research.
PosterProteomic Indicators of Metabolic Health in Diabetes and Social Deprivation
Understanding the health impacts of socioeconomic deprivation (SED) and its interaction with type 2 diabetes is important for patient care and effective public health initiatives. Large-scale proteomic profiling using aptamer-based technology to measure 7,000 proteins has facilitated the development of blood-based proteomic signatures for 11 cardiometabolic SomaSignalTM Tests (SST)
PosterHeritability, pQTLs, and environmental influence on proteins involved in age, cardiovascular risk, and glucose tolerance using the SomaScan® Assay
Protein quantitative trait locus (“pQTL”) studies identify genetic variants that are statistically associated with protein levels. Results from the growing number of pQTL studies can be combined with genome-wide association studies to identify proteins that underlie the genetic risk of disease, thus revealing the mechanisms of disease and potential drug targets.